🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

8 recruiting trials

for Pancreatic Neuroendocrine Tumor With Liver Metastases

Lenvatinib Plus Chemotherapy for pNET Liver Metastases NCT07835893Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Lenvatinib, Chemotherapy IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors NCT06016855Phase 41 site📍 Nashville Vanderbilt-Ingram Cancer Center · Tests: Tumor Debulking, Lutetium Lu 177 Dotatate, Computed Tomography, Magnetic Resonance Imaging, Copper Cu 64 Dotatate EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype NCT06753136NA1 site📍 Padova Istituto Oncologico Veneto IRCCS · Tests: percutaneous, laparoscopic or laparotomy lesion electrochemotherapy SL-28 for Advanced Solid Tumours NCT07341737Phase 1, Phase 23 sites📍 Sydney📍 Gold Coast📍 Adelaide Second Life Therapeutics · Tests: SL-28, SL-28, SL-28 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy